PreveCeutical Medical (PRVC.F) Stock Overview
A health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PRVC.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
PreveCeutical Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.015 |
| 52 Week High | CA$0.044 |
| 52 Week Low | CA$0.0037 |
| Beta | 0.24 |
| 1 Month Change | 31.82% |
| 3 Month Change | 38.10% |
| 1 Year Change | -32.87% |
| 3 Year Change | -19.89% |
| 5 Year Change | -24.48% |
| Change since IPO | -87.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| PRVC.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -18.5% | -3.4% | -0.9% |
| 1Y | -32.9% | 45.9% | 13.9% |
Return vs Industry: PRVC.F underperformed the US Pharmaceuticals industry which returned 45.9% over the past year.
Return vs Market: PRVC.F underperformed the US Market which returned 13.9% over the past year.
Price Volatility
| PRVC.F volatility | |
|---|---|
| PRVC.F Average Weekly Movement | 45.8% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PRVC.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PRVC.F's weekly volatility has decreased from 89% to 46% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Stephen Van Deventer | www.preveceutical.com |
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its research and development of preventive and therapeutic products derived from organic and nature-identical compounds; synthesized Nature Identical; Sol-Gel Nose-to-Brain delivery platform for Parkinson’s disease; develops cannabinoid-based nose-to-brain delivery system for the relief of a various ailments, including pain, inflammation, seizures, and neurological disorders; peptide library synthesis, pharmacological evaluation, alongside pharmacokinetic assessment, and determinations in animal models of pain and inflammation; and non-addictive analgesic peptides for pain management. It also involved in licensing, branding, and marketing nutraceutical and wellness products; Sol-Gel platform; and peptide program.
PreveCeutical Medical Inc. Fundamentals Summary
| PRVC.F fundamental statistics | |
|---|---|
| Market cap | US$9.17m |
| Earnings (TTM) | -US$495.42k |
| Revenue (TTM) | n/a |
Is PRVC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRVC.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$689.28k |
| Earnings | -CA$689.28k |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0011 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -72.4% |
How did PRVC.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 22:00 |
| End of Day Share Price | 2026/09/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PreveCeutical Medical Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.